Skip to main content
. 2023 Feb 18;48(2):141–150. doi: 10.1007/s13318-023-00815-x

Table 3.

Pharmacokinetic results by palovarotene dose and Japanese/non-Japanese group

Parameter, units Palovarotene 5 mg Palovarotene 10 mg
Japanese participants (N = 10) Non-Japanese participants (N = 8) Japanese participants (N = 10) Non-Japanese participants (N = 8)
AUC(0–∞), h·ng/mL
 Geometric meana 214.7 240.6 428.8 451.2
 Coefficient of variation %b 29.5 45.7 27.0 43.6
 90% CIa (176.9, 260.5) (193.8, 298.7) (353.4, 520.3) (363.5, 560.2)
 Ratio of geometric meana 0.9 1.0
 90% CI for ratioa (0.7, 1.2) (0.7, 1.3)
AUC(0–z), h·ng/mL
 Geometric meana 213.9 240.1 427.8 448.3
 Coefficient of variation %b 29.2 45.8 26.9 44.4
 90% CIa (176.2, 259.8) (193.3, 298.4) (352.3, 519.5) (360.8, 557.0)
 Ratio of geometric meana 0.9 1.0
 90% CI for ratioa (0.7, 1.2) (0.7, 1.3)
Cmax, ng/mL
 Geometric meana 38.2 39.7 74.4 77.9
 Coefficient of variation %b 42.7 37.9 29.0 30.6
 90% CIa (31.6, 46.2) (32.1, 49.1) (61.5, 90.1) (63.0, 96.4)
 Ratio of geometric meana 1.0 1.0
 90% CI for ratioa (0.7, 1.3) (0.7, 1.3)

aGeometric means and CIs obtained from a mixed model with fixed effects for groups and doses and a random participant effect. bCoefficient of variation % = (sqrt((exp(variance of natural log-transformed data)) - 1)) × 100

AUC area under the plasma concentration–time curve, AUC(0–z) AUC from time zero to the last timepoint, AUC(0–∞) AUC from time zero to infinity, CI confidence interval, Cmax maximum plasma drug concentration, N number of participants